Cargando…
Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
The recent development of immunotherapy represents a significant breakthrough in cancer therapy. Several immunotherapies provide robust efficacy gains in a wide variety of cancers. However, in some patients the immune checkpoint blockade remains ineffective due to poor therapeutic response and tumor...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961218/ https://www.ncbi.nlm.nih.gov/pubmed/35339889 http://dx.doi.org/10.1016/j.tranon.2022.101405 |
_version_ | 1784677550050508800 |
---|---|
author | Rupp, Tristan Genest, Laurie Babin, David Legrand, Christophe Hunault, Marion Froget, Guillaume Castagné, Vincent |
author_facet | Rupp, Tristan Genest, Laurie Babin, David Legrand, Christophe Hunault, Marion Froget, Guillaume Castagné, Vincent |
author_sort | Rupp, Tristan |
collection | PubMed |
description | The recent development of immunotherapy represents a significant breakthrough in cancer therapy. Several immunotherapies provide robust efficacy gains in a wide variety of cancers. However, in some patients the immune checkpoint blockade remains ineffective due to poor therapeutic response and tumor relapse. An improved understanding of the mechanisms underlying tumor-immune system interactions can improve clinical management of cancer. Here, we report preclinical data evaluating two murine antibodies corresponding to recent FDA-approved antibodies for human therapy, e.g. anti-CTLA-4 and anti-PD-1. We demonstrated in two mouse syngeneic grafting models of triple negative breast or colon cancer that the two antibodies displayed an efficient anticancer activity, which is enhanced by combination treatment in the breast cancer model. We also demonstrated that CTLA-4 targeting reduced metastasis formation in the colon cancer metastasis model. In addition, using cytometry-based multiplex analysis, we showed that anti-CTLA-4 and anti-PD-1 affected the tumor immune microenvironment differently and in particular the tumor immune infiltration. This work demonstrated anti-cancer effect of CTLA-4 or PD-1 blockade on mouse colon and triple negative breast and on tumor-infiltrating immune cell subpopulations that could improve our knowledge and benefit the breast and colon cancer tumor research community. |
format | Online Article Text |
id | pubmed-8961218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-89612182022-04-07 Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response Rupp, Tristan Genest, Laurie Babin, David Legrand, Christophe Hunault, Marion Froget, Guillaume Castagné, Vincent Transl Oncol Perspective The recent development of immunotherapy represents a significant breakthrough in cancer therapy. Several immunotherapies provide robust efficacy gains in a wide variety of cancers. However, in some patients the immune checkpoint blockade remains ineffective due to poor therapeutic response and tumor relapse. An improved understanding of the mechanisms underlying tumor-immune system interactions can improve clinical management of cancer. Here, we report preclinical data evaluating two murine antibodies corresponding to recent FDA-approved antibodies for human therapy, e.g. anti-CTLA-4 and anti-PD-1. We demonstrated in two mouse syngeneic grafting models of triple negative breast or colon cancer that the two antibodies displayed an efficient anticancer activity, which is enhanced by combination treatment in the breast cancer model. We also demonstrated that CTLA-4 targeting reduced metastasis formation in the colon cancer metastasis model. In addition, using cytometry-based multiplex analysis, we showed that anti-CTLA-4 and anti-PD-1 affected the tumor immune microenvironment differently and in particular the tumor immune infiltration. This work demonstrated anti-cancer effect of CTLA-4 or PD-1 blockade on mouse colon and triple negative breast and on tumor-infiltrating immune cell subpopulations that could improve our knowledge and benefit the breast and colon cancer tumor research community. Neoplasia Press 2022-03-24 /pmc/articles/PMC8961218/ /pubmed/35339889 http://dx.doi.org/10.1016/j.tranon.2022.101405 Text en © 2022 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Perspective Rupp, Tristan Genest, Laurie Babin, David Legrand, Christophe Hunault, Marion Froget, Guillaume Castagné, Vincent Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response |
title | Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response |
title_full | Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response |
title_fullStr | Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response |
title_full_unstemmed | Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response |
title_short | Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response |
title_sort | anti-ctla-4 and anti-pd-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory t cells response |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961218/ https://www.ncbi.nlm.nih.gov/pubmed/35339889 http://dx.doi.org/10.1016/j.tranon.2022.101405 |
work_keys_str_mv | AT rupptristan antictla4andantipd1immunotherapiesrepresstumorprogressioninpreclinicalbreastandcolonmodelwithindependentregulatorytcellsresponse AT genestlaurie antictla4andantipd1immunotherapiesrepresstumorprogressioninpreclinicalbreastandcolonmodelwithindependentregulatorytcellsresponse AT babindavid antictla4andantipd1immunotherapiesrepresstumorprogressioninpreclinicalbreastandcolonmodelwithindependentregulatorytcellsresponse AT legrandchristophe antictla4andantipd1immunotherapiesrepresstumorprogressioninpreclinicalbreastandcolonmodelwithindependentregulatorytcellsresponse AT hunaultmarion antictla4andantipd1immunotherapiesrepresstumorprogressioninpreclinicalbreastandcolonmodelwithindependentregulatorytcellsresponse AT frogetguillaume antictla4andantipd1immunotherapiesrepresstumorprogressioninpreclinicalbreastandcolonmodelwithindependentregulatorytcellsresponse AT castagnevincent antictla4andantipd1immunotherapiesrepresstumorprogressioninpreclinicalbreastandcolonmodelwithindependentregulatorytcellsresponse |